Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Lemonnier

Showing results (241-250 of 264) with videos related to

Pageof 27
Sort By:
International Immunology|December 30, 2004
The non-classical HLA class I molecule HFE does not influence the NK-like activity contained in fresh human PBMCs and does not interact with NK cellsSteve Pascolo, Florent Ginhoux, Nihay Laham, et al.
Cancer Immunology, Immunotherapy : CII|May 10, 2007
HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptidesMorgan G Mathieu, Ashley J Knights, Graham Pawelec, et al.
Journal of Virology|June 11, 1999
Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopesT Woodberry, J Gardner, L Mateo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 8, 1999
Cutting edge: expression of functional CD94/NKG2A inhibitory receptors on fetal NK1.1+Ly-49- cells: a possible mechanism of tolerance during NK cell developmentP V Sivakumar, A Gunturi, M Salcedo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 19, 2013
HLA-A*01:03, HLA-A*24:02, HLA-B*08:01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 monochain transgenic/H-2 class I null mice: novel versatile preclinical models of human T cell responsesRachid Boucherma, Hédia Kridane-Miledi, Romain Bouziat, et al.
HLA|October 1, 2024
Characterisation of the HLA-DQ alpha eplet 52SK targeting the DQA1*01 alleles familyMagali Devriese, Jar How Lee, Tina Meng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGEYoshihiro Miyahara, Hiroaki Naota, Lijie Wang, et al.
Human Immunology|May 1, 1997
The diversity of antigen-specific TCR repertoires reflects the relative complexity of epitopes recognizedJ L Maryanski, J L Casanova, K Falk, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2024
Separating the Wheat from the Chaff among HLA-DQ EpletsMagali Devriese, François A Lemonnier, Julien Lion, et al.
Cancer Immunology, Immunotherapy : CII|April 20, 2006
STEAP, a prostate tumor antigen, is a target of human CD8+ T cellsPedro M S Alves, Olivier Faure, Stéphanie Graff-Dubois, et al.
Pageof 27

Showing results (241-250 of 264) with videos related to

Sort By:
Pageof 27
International Immunology|December 30, 2004
The non-classical HLA class I molecule HFE does not influence the NK-like activity contained in fresh human PBMCs and does not interact with NK cellsSteve Pascolo, Florent Ginhoux, Nihay Laham, et al.
Cancer Immunology, Immunotherapy : CII|May 10, 2007
HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptidesMorgan G Mathieu, Ashley J Knights, Graham Pawelec, et al.
Journal of Virology|June 11, 1999
Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopesT Woodberry, J Gardner, L Mateo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 8, 1999
Cutting edge: expression of functional CD94/NKG2A inhibitory receptors on fetal NK1.1+Ly-49- cells: a possible mechanism of tolerance during NK cell developmentP V Sivakumar, A Gunturi, M Salcedo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 19, 2013
HLA-A*01:03, HLA-A*24:02, HLA-B*08:01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 monochain transgenic/H-2 class I null mice: novel versatile preclinical models of human T cell responsesRachid Boucherma, Hédia Kridane-Miledi, Romain Bouziat, et al.
HLA|October 1, 2024
Characterisation of the HLA-DQ alpha eplet 52SK targeting the DQA1*01 alleles familyMagali Devriese, Jar How Lee, Tina Meng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGEYoshihiro Miyahara, Hiroaki Naota, Lijie Wang, et al.
Human Immunology|May 1, 1997
The diversity of antigen-specific TCR repertoires reflects the relative complexity of epitopes recognizedJ L Maryanski, J L Casanova, K Falk, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2024
Separating the Wheat from the Chaff among HLA-DQ EpletsMagali Devriese, François A Lemonnier, Julien Lion, et al.
Cancer Immunology, Immunotherapy : CII|April 20, 2006
STEAP, a prostate tumor antigen, is a target of human CD8+ T cellsPedro M S Alves, Olivier Faure, Stéphanie Graff-Dubois, et al.
Pageof 27